Nordic Pharma to Share LACRIFILL® Benefits at AAO 2026

DOYLESTOWN, Pa., Oct. 7, 2026 /CourierPR/ -- Nordic Pharma, Inc., a subsidiary of SEVER Life Sciences B.V., will feature LACRIFILL® Canalicular Gel, a novel therapy for ocular surface control, during the American Academy of Ophthalmology Annual Meeting in New Orleans, Louisiana, from October 9 to 12. The gel is being used by over 2,200 ophthalmology and optometry practices across the United States, with more than 130,000 patients having been treated with this innovative therapy.

During the meeting, attendees will have the opportunity to see eye care professionals administering LACRIFILL Canalicular Gel on Saturday, October 10, and Sunday, October 11, from 10:00 a.m. to 4:00 p.m. at the Nordic Pharma booth (#3136). The booth will feature demonstrations and the chance for attendees to place orders.

In a recent patient experience survey, 96% of respondents who had cataract surgery within the past six months, and 91% of all patients surveyed, reported that LACRIFILL Canalicular Gel made their eyes feel better. Dr. Jai G. Parekh, Chief Commercial Officer of Nordic Pharma, Inc., expressed excitement about sharing the benefits of the therapy with attendees.

Dr. David Szynkarski, of Mann Eye Institute, also highlighted the benefits of the gel. Mann Eye Institute is committed to pioneering advances in eye care technology and has seen success with LACRIFILL Canalicular Gel.

The gel is particularly beneficial for patients undergoing cataract or refractive surgery, as well as those managing symptoms and reducing reliance on drops for dry eye disease. According to the company, LACRIFILL Canalicular Gel is indicated for up to six months of use, providing long-term postoperative benefits. The therapy is designed to control the ocular surface following surgery, supporting postoperative recovery, patient satisfaction, and quality of life.

Eye care professionals recognize that the American Academy of Ophthalmology provides an outstanding opportunity to learn about the latest advancements in ophthalmology and how they benefit their patients. SEVER Life Sciences is a global private specialty pharmaceutical holding company committed to helping people around the world live better lives. Headquartered in the Netherlands, SEVER Life Sciences brings together three diverse but complementary companies that offer a wide range of products, pharmaceutical development services, and delivery technologies.

Nordic Pharma, Inc., partnered with well-established global biopharmaceutical companies, is uniquely positioned to leverage its expertise in bringing medical devices and sterile manufacturing to the marketplace. The company is excited to share data that support the benefits of LACRIFILL Canalicular Gel, including greater comfort and more stable vision in both post-surgical applications and for treatment of dry eye disease.